Ghrelin agonist evidence
Relamorelin for Gastroparesis: Ghrelin Agonist Evidence and Phase 3 Limits
A careful review of relamorelin and RM-131 for diabetic gastroparesis: ghrelin receptor mechanism, phase 2 human trial signals, glycemic-control concerns, terminated phase 3 records, and claim limits.
Relamorelin is a synthetic ghrelin receptor agonist that was studied for diabetic gastroparesis, a condition marked by delayed gastric emptying without a mechanical obstruction. It is also called RM-131 in older trial records and papers. The search intent is usually practical: did relamorelin help vomiting, did it speed gastric emptying, did phase 3 succeed, and is it available as a treatment?
The short answer is evidence-aware, not promotional. Human phase 2 studies reported meaningful signals in diabetic gastroparesis, especially around gastric emptying and vomiting-related outcomes. At the same time, multiple phase 3 ClinicalTrials.gov records are listed as terminated, and this review did not identify an FDA-approved relamorelin label. Earlier promise should not be rewritten as established treatment.
Relamorelin also sits near a peptide-market confusion point. Ghrelin receptor language appears in ipamorelin discussions, and the ipamorelin mechanism guide explains growth hormone secretagogue biology. Relamorelin was developed for gastrointestinal motility. Those two evidence packages should stay separate.
The topic also contrasts with GLP-1 drug safety discussions. Ozempic gastroparesis and ileus evidence covers delayed gastric emptying and label warnings for semaglutide. Relamorelin was studied as a prokinetic candidate. That contrast is useful biology, but it does not make relamorelin an unapproved workaround for semaglutide, tirzepatide, or other metabolic medicines.
Evidence Snapshot
| Common claim | Evidence picture | Boundary |
|---|---|---|
| Relamorelin is a general gut-motility peptide. | Relamorelin, also called RM-131, is a synthetic pentapeptide ghrelin receptor agonist studied mainly in diabetic gastroparesis and other motility settings. | Gastroparesis is a specific delayed gastric emptying syndrome, not a broad gut-health category. |
| Phase 2 results mean it is established treatment. | Randomized phase 2 studies reported acceleration of gastric emptying and symptom signals, especially vomiting-related outcomes. | Phase 3 ClinicalTrials.gov records for diabetic gastroparesis are listed as terminated, and no approved relamorelin label was identified in this review. |
| A ghrelin mechanism proves clinical benefit. | Ghrelin receptor activation gives a plausible prokinetic mechanism and overlaps conceptually with growth hormone secretagogue biology. | Mechanism is not an outcome. Symptoms, gastric-emptying tests, glycemic effects, durability, and regulatory review still matter. |
| Relamorelin is like ipamorelin for digestion. | Both topics involve ghrelin receptor language, but relamorelin was developed as a gastrointestinal prokinetic candidate. | Ipamorelin evidence and relamorelin evidence should not be merged into one consumer peptide claim. |
| GLP-1 gastroparesis and relamorelin answer the same question. | GLP-1 drugs can delay gastric emptying, while relamorelin was studied to accelerate gastric emptying in diabetic gastroparesis. | That contrast is biologically relevant, but it does not make relamorelin a workaround for GLP-1 adverse effects or a self-directed treatment. |
What Relamorelin Is
Relamorelin is a synthetic pentapeptide agonist of the ghrelin receptor, also known as the growth hormone secretagogue receptor 1a. The phrase "ghrelin agonist" can sound like appetite or hormone marketing, but the gastroparesis program focused on motility. Ghrelin signaling can affect gastric emptying, antral contractility, and broader gastrointestinal transit.
Diabetic gastroparesis is not just nausea after meals. It is delayed gastric emptying in the setting of diabetes after mechanical obstruction has been excluded. Symptoms can include vomiting, nausea, early satiety, bloating, postprandial fullness, abdominal pain, glucose variability, nutrition problems, and poor quality of life. Because symptoms and gastric emptying do not always move together, a trial needs both patient-reported outcomes and objective emptying measures.
Relamorelin was given by subcutaneous injection in the main diabetic gastroparesis trials. That route matters because oral supplement comparisons or research-vial claims do not recreate the protocol, product, eligibility criteria, or outcome measurement. The broader product-category distinction is covered in approved, investigational, compounded, and research peptides.
Mechanism should be treated as a starting point. Preclinical and early pharmacology papers support a prokinetic rationale, but clinical relevance depends on human outcomes. A peptide can move a mechanistic marker and still fail to become a practical therapy if symptoms, safety, durability, manufacturing, regulatory review, or trial execution do not support use.
What The Human Trials Reported
A 2016 randomized double-blind trial enrolled 204 adults with diabetic gastroparesis, moderate to severe symptoms, and delayed gastric emptying. Participants received placebo or subcutaneous relamorelin 10 micrograms once or twice daily. Twice-daily relamorelin accelerated gastric emptying and reduced vomiting frequency and severity versus placebo. Other symptoms, such as abdominal pain and satiety, did not all improve in the full population.
The subgroup with vomiting at baseline is important because it helps explain why relamorelin remained interesting. In that group, twice-daily relamorelin improved gastric emptying, vomiting, and a composite symptom score. That does not mean every person with dyspepsia, bloating, or slow digestion has the same expected response. It means the studied population and baseline symptom pattern mattered.
A later phase 2B trial enrolled 393 participants with moderate to severe diabetic gastroparesis symptoms. It tested placebo against relamorelin 10, 30, or 100 micrograms twice daily for 12 weeks. The study reported significant reductions in core symptom scores over time and acceleration of gastric emptying for the 10 and 30 microgram groups. Vomiting frequency fell from baseline in relamorelin groups, but the difference versus placebo was not significant for that endpoint.
Safety interpretation needs the same restraint. The phase 2B paper reported dose-related worsening of glycemic control in 14.5 percent of participants receiving relamorelin, with some requiring adjustments to insulin or other diabetes medicines. In diabetic gastroparesis, glucose management is already part of the disease problem, so a glycemic-control signal is clinically relevant.
| Evidence setting | Design context | How to read it |
|---|---|---|
| Phase 2 diabetic gastroparesis trial | 204 adults with diabetic gastroparesis and delayed gastric emptying were randomized to placebo or subcutaneous relamorelin. | Twice-daily relamorelin accelerated gastric emptying and reduced vomiting frequency and severity, but not every symptom endpoint improved. |
| Phase 2B diabetic gastroparesis trial | 393 participants with moderate to severe diabetic gastroparesis symptoms received placebo or several twice-daily relamorelin doses. | Core symptom scores and gastric emptying improved versus placebo, while dose-related glycemic-control worsening was reported. |
| Pooled phase 2 safety analysis | Published safety analysis across phase 2a and phase 2b diabetic gastroparesis data. | Useful for tolerability context, but it remains pre-approval evidence and cannot define routine clinical use. |
| Phase 3 program records | Multiple ClinicalTrials.gov phase 3 diabetic gastroparesis records are listed as terminated. | Terminated phase 3 status is a major boundary for claims based only on earlier promising trials. |
The best reading is balanced. Human evidence indicates that relamorelin produced prokinetic and symptom signals in diabetic gastroparesis trials. The evidence does not establish routine clinical use, broad digestive enhancement, or seller-dose guidance.
Why The Phase 3 Status Changes The Claim
ClinicalTrials.gov lists multiple phase 3 relamorelin diabetic gastroparesis studies as terminated, including study records NCT03285308, NCT03426345, NCT03383146, and NCT03786380. Those records matter because phase 3 is where a promising phase 2 signal is usually tested at larger scale for an approval-grade evidence package.
A terminated trial record is not the same as a peer-reviewed negative paper, but it is a major claim boundary. It means a page should not present relamorelin as if development cleanly progressed from mechanism to phase 2 to approval. It should say that phase 2 findings were promising enough to justify further study, while later development did not produce an identified approved treatment role.
This is where research literacy matters. A seller page can quote a phase 2 abstract and omit the phase 3 status. A patient forum can mention symptom relief and omit trial design. A mechanism review can describe ghrelin receptor biology and omit regulatory outcomes. A reliable summary needs all of those buckets separated.
The how to read a peptide study guide is useful here because relamorelin has several evidence layers: preclinical prokinetic data, phase 2 human trials, pooled safety analysis, meta-analysis, and terminated phase 3 records. Those layers should not be collapsed into one confidence level.
Safety And Product Limits
Relamorelin is not a generic motility supplement. The diabetic gastroparesis trials used defined subcutaneous dosing, inclusion criteria, symptom diaries, gastric-emptying tests, and diabetes monitoring. Research-market products do not inherit those controls.
Glycemic-control concerns deserve special attention. Diabetic gastroparesis already creates difficult timing between food absorption, gastric emptying, insulin, oral diabetes medicines, and glucose swings. A medication that changes gastric emptying or ghrelin receptor signaling can change that balance. The phase 2B report specifically described dose-related worsening of glycemic control in a subset of participants.
Growth hormone secretagogue biology should also be kept in context. Relamorelin has ghrelin receptor activity, and the ghrelin receptor is also central to topics such as CJC-1295 and ipamorelin stack rationale. That overlap does not let readers import body-composition, appetite, hormone, or anti-aging claims into a gastroparesis trial. It also does not let relamorelin trial results validate ipamorelin protocols.
The reconstitution calculator can help with concentration math, and the reconstitution math guide explains units. Neither can answer whether a person has gastroparesis, whether gastric-emptying testing is valid, whether a motility drug is appropriate, or how diabetes medication should be adjusted.
How To Check Relamorelin Claims
First, look for the population. Diabetic gastroparesis with delayed gastric emptying is not the same as general bloating, reflux, appetite changes, GLP-1 nausea, or constipation. A claim should name the studied condition.
Second, look for the endpoint. Gastric-emptying acceleration, vomiting frequency, nausea, bloating, abdominal pain, early satiety, and composite symptom scores are related but not interchangeable. A claim based on one endpoint should not imply improvement in all symptoms.
Third, check the trial phase. Phase 2 signals are important, but terminated phase 3 records mean the evidence package should be described as limited and not approval-established. That is the main difference between a careful relamorelin summary and a promotional one.
Fourth, separate relamorelin from GLP-1 safety conversations. The GLP-1 surgery and aspiration guide and GLP-1 pancreatitis and gallbladder guide address different drug classes, labels, and risk questions. Relamorelin evidence should not be used to self-manage adverse effects from prescription metabolic medicines.
Fifth, be cautious with product claims. A COA can support limited identity or purity checks, but it cannot establish diabetic gastroparesis efficacy, glycemic safety, sterility, route suitability, or clinical monitoring. Use the COA red flags guide before treating lab paperwork as a medical evidence package.
FAQ
Is relamorelin a peptide?
Yes. Relamorelin is a synthetic pentapeptide ghrelin receptor agonist studied as a gastrointestinal prokinetic candidate.
Is relamorelin approved for gastroparesis?
This review did not identify an approved relamorelin label. Multiple phase 3 diabetic gastroparesis records are listed as terminated on ClinicalTrials.gov.
What did phase 2 studies show?
Phase 2 studies reported acceleration of gastric emptying and symptom signals, especially vomiting-related outcomes, but results varied by endpoint and population.
Can relamorelin be used to counter GLP-1 delayed gastric emptying?
The evidence reviewed here does not establish that use. GLP-1 adverse effects, gastroparesis, diabetes management, and motility-drug decisions require clinician-directed evaluation.
References
- Relamorelin Reduces Vomiting Frequency and Severity and Accelerates Gastric Emptying in Adults With Diabetic Gastroparesis, Gastroenterology / PubMed.
- Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study, Gastroenterology / PubMed.
- Overall safety of relamorelin in adults with diabetic gastroparesis: Analysis of phase 2a and 2b trial data, Alimentary Pharmacology and Therapeutics / PubMed.
- Emerging treatments in Neurogastroenterology: relamorelin: a novel gastrocolokinetic synthetic ghrelin agonist, Neurogastroenterology and Motility / PubMed.
- Diabetic gastroparesis: An overview of pathogenesis, clinical presentation and novel therapies, with a focus on ghrelin receptor agonists, Journal of Diabetes and Its Complications / PubMed.
- Relamorelin in Gastroparesis and Diabetic Gastroparesis: A Meta-Analysis on Its Efficacy and Safety, Cureus / PubMed.
- Preclinical gastrointestinal prokinetic efficacy and endocrine effects of the ghrelin mimetic RM-131, Life Sciences / PubMed.
- Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis: NCT02357420, ClinicalTrials.gov.
- A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01: NCT03285308, ClinicalTrials.gov.
- Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02: NCT03426345, ClinicalTrials.gov.
- Diabetic Gastroparesis Study 05: NCT03786380, ClinicalTrials.gov.
Disclaimer
This page is educational and is not medical advice. It does not provide gastroparesis diagnosis, diabetes medication guidance, GLP-1 adverse-event management, motility-drug recommendations, reconstitution guidance, dosing, sourcing, compounding, or individualized safety advice for relamorelin, RM-131, ghrelin agonists, gastroparesis, or related products. Symptoms such as vomiting, delayed gastric emptying, weight loss, dehydration, glucose instability, or suspected medication adverse effects should be handled with qualified clinicians using current diagnostic standards and patient-specific risk factors.
Next steps
Continue with the closest guide, peptide profile, or research tool.
